Viridian Therapeutics ( (VRDN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Viridian Therapeutics’ stock is on the rise following a series of Buy ratings from analysts, spurred by promising developments such as the BLA submission and potential launch of veligrotug for thyroid eye disease. The company’s recent quarterly earnings report revealed significant revenue growth, which has positively impacted stock price targets, despite a notable net loss. Analysts have raised price targets due to strategic moves towards profitability and promising future prospects.
More about Viridian Therapeutics
YTD Price Performance: 53.54%
Average Trading Volume: 1,251,776
Technical Sentiment Signal: Buy
Current Market Cap: $2.9B
For further insights into VRDN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.